Abdulhakim A. Alzahrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abdulhakim A. Alzahrani has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Bassant Mohamed Barakat
Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Baha University, Al-Baha 65779, Saudi Arabia
2 shared publications - Mohammad Aref Albanghali
Department of Public Health, Faculty of Applied Medical Sciences, Al-Baha University, Al Baha 65779, Saudi Arabia
2 shared publications - Saleh Alghamdi
Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Baha University, Al-Baha, Saudi Arabia
2 shared publications - Abdul Haseeb
Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
1 shared publication - Abdullah Sameer Alshammari
Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah 24237, Saudi Arabia
1 shared publication - Abdulmajeed Abdulghani A. Sindi
Department of Basic Medical Sciences, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 4 August 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 753
National Antimicrobial Stewardship Performance and Antimicrobial Use in Saudi Ministry of Health Hospitals: A Four-Year Multicenter Surveillance Analysis, 2021–2024
Background/Objectives: Antimicrobial stewardship programmes (ASPs) are essential for improving antimicrobial use and limiting the emergence of antimicrobial resistance. Although national ASP key performance indicators (KPIs) have been implemented across Saudi Ministry of Health (MOH) hospitals, large-scale evaluations of programme performance remain limited. This study evaluated national ASP performance across MOH hospitals from 2021 to 2024 using formal KPIs and complementary stewardship measures. Methods: This retrospective multicentre surveillance analysis included 124,452 antimicrobial prescription reviews from 96 Saudi MOH hospitals actively reporting stewardship activities. Hospitals were classified according to ASP capacity as category A, B, or C. The evaluated KPIs included protocol adherence, restricted-antibiotic dispensing compliance, active intervention rate, annual trends in optimization interventions, and physician acceptance of ASP recommendations. Secondary assessments included appropriateness of therapy management, therapeutic drug monitoring (TDM) for vancomycin and aminoglycosides, and hospital-level antimicrobial use expressed as defined daily doses per 100 available bed-days. Multivariable logistic regression was used to identify factors associated with guideline non-adherence and physician non-acceptance. Results: Overall protocol adherence was 87.1%, exceeding the national target of 80%, while the active intervention rate was 64.6%, exceeding the 60% benchmark. Restricted-antibiotic dispensing compliance reached 87.6% but remained below the 100% target. Physician acceptance of ASP recommendations was high at 93.0%, although it did not achieve the national target of 98%. The optimization-intervention KPI was not met because de-escalation, antibiotic discontinuation, and intravenous-to-oral conversion did not demonstrate a sustained annual increase. Appropriate ongoing therapy management was documented in 68.3% of cases with available data, whereas TDM was requested in 44.5% of eligible vancomycin or aminoglycoside cases. Antimicrobial use varied across years and hospital categories, with higher monitored broad-spectrum and reserve-agent use in higher-capacity hospitals. Lower ASP capacity, non-critical care settings, and combination therapy were consistently associated with less favourable stewardship outcomes. Conclusions: Saudi MOH hospitals actively reporting stewardship activities demonstrated favourable performance in protocol adherence, intervention activity, and physician acceptance. However, persistent gaps in restricted-antibiotic dispensing, optimization interventions, TDM, and inter-hospital variation indicate the need for continued strengthening of ASP infrastructure, monitoring, and feedback systems. Future research should link stewardship indicators with clinical outcomes, antimicrobial resistance trends, and patient safety.
- 4 August 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 753
Open AccessNational Antimicrobial Stewardship Performance and Antimicrobial Use in Saudi Ministry of Health Hospitals: A Four-Year Multicenter Surveillance Analysis, 2021–2024
Background/Objectives: Antimicrobial stewardship programmes (ASPs) are essential for improving antimicrobial use and limiting the emergence of antimicrobial resistance. Although national ASP key performance indicators (KPIs) have been implemented across Saudi Ministry of Health (MOH) hospitals, large-scale evaluations of programme performance remain limited. This study evaluated national ASP performance across MOH hospitals from 2021 to 2024 using formal KPIs and complementary stewardship measures. Methods: This retrospective multicentre surveillance analysis included 124,452 antimicrobial prescription reviews from 96 Saudi MOH hospitals actively reporting stewardship activities. Hospitals were classified according to ASP capacity as category A, B, or C. The evaluated KPIs included protocol adherence, restricted-antibiotic dispensing compliance, active intervention rate, annual trends in optimization interventions, and physician acceptance of ASP recommendations. Secondary assessments included appropriateness of therapy management, therapeutic drug monitoring (TDM) for vancomycin and aminoglycosides, and hospital-level antimicrobial use expressed as defined daily doses per 100 available bed-days. Multivariable logistic regression was used to identify factors associated with guideline non-adherence and physician non-acceptance. Results: Overall protocol adherence was 87.1%, exceeding the national target of 80%, while the active intervention rate was 64.6%, exceeding the 60% benchmark. Restricted-antibiotic dispensing compliance reached 87.6% but remained below the 100% target. Physician acceptance of ASP recommendations was high at 93.0%, although it did not achieve the national target of 98%. The optimization-intervention KPI was not met because de-escalation, antibiotic discontinuation, and intravenous-to-oral conversion did not demonstrate a sustained annual increase. Appropriate ongoing therapy management was documented in 68.3% of cases with available data, whereas TDM was requested in 44.5% of eligible vancomycin or aminoglycoside cases. Antimicrobial use varied across years and hospital categories, with higher monitored broad-spectrum and reserve-agent use in higher-capacity hospitals. Lower ASP capacity, non-critical care settings, and combination therapy were consistently associated with less favourable stewardship outcomes. Conclusions: Saudi MOH hospitals actively reporting stewardship activities demonstrated favourable performance in protocol adherence, intervention activity, and physician acceptance. However, persistent gaps in restricted-antibiotic dispensing, optimization interventions, TDM, and inter-hospital variation indicate the need for continued strengthening of ASP infrastructure, monitoring, and feedback systems. Future research should link stewardship indicators with clinical outcomes, antimicrobial resistance trends, and patient safety.
- Open Access
- 31 March 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (4) , 365
Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia
The aim of this study was to assess the clinical effectiveness of Hydroxychloroquine-based regimens versus standard treatment in patients with the coronavirus disease admitted in 2019 to a hospital in Saudi Arabia. A comparative observational study, using routine hospital data, was carried out in a large tertiary care hospital in Al Baha, Saudi Arabia, providing care to patients with COVID-19 between April 2019 and August 2019. Patients were categorized into two groups: the Hydroxychloroquine (HCQ) group, treated with HCQ in a dose of 400 mg twice daily on the first day, followed by 200 mg twice daily; the non HCQ group, treated with other antiviral or antibacterial treatments according to protocols recommended by the Ministry of Health (MOH) at the time. The primary outcomes were the length of hospital stay, need for admission to the intensive care unit (ICU), time in ICU, and need for mechanical ventilation. Overall survival was also assessed. 568 patients who received HCQ (treatment group) were compared with 207 patients who did not receive HCQ (control group). HCQ did not improve mortality in the treated group (7.7% vs. 7.2%). There were no significant differences in terms of duration of hospitalization, need for and time in ICU, and need for mechanical ventilation among the groups. Our study provides further evidence that HCQ treatment does not reduce mortality rates, length of hospital stay, admission and time in ICU, and need for mechanical ventilation in patients hospitalized with COVID-19.
- 31 March 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (4) , 365
Open AccessClinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia
The aim of this study was to assess the clinical effectiveness of Hydroxychloroquine-based regimens versus standard treatment in patients with the coronavirus disease admitted in 2019 to a hospital in Saudi Arabia. A comparative observational study, using routine hospital data, was carried out in a large tertiary care hospital in Al Baha, Saudi Arabia, providing care to patients with COVID-19 between April 2019 and August 2019. Patients were categorized into two groups: the Hydroxychloroquine (HCQ) group, treated with HCQ in a dose of 400 mg twice daily on the first day, followed by 200 mg twice daily; the non HCQ group, treated with other antiviral or antibacterial treatments according to protocols recommended by the Ministry of Health (MOH) at the time. The primary outcomes were the length of hospital stay, need for admission to the intensive care unit (ICU), time in ICU, and need for mechanical ventilation. Overall survival was also assessed. 568 patients who received HCQ (treatment group) were compared with 207 patients who did not receive HCQ (control group). HCQ did not improve mortality in the treated group (7.7% vs. 7.2%). There were no significant differences in terms of duration of hospitalization, need for and time in ICU, and need for mechanical ventilation among the groups. Our study provides further evidence that HCQ treatment does not reduce mortality rates, length of hospital stay, admission and time in ICU, and need for mechanical ventilation in patients hospitalized with COVID-19.